Indian companies are unable to raise prices because 35 per cent of the drugs sold in the country come under the government's price control order.
Through this, the company plans to bid for 35 non-metro airports coming up for development in India as well as international airport developments.
With financial results for the quarter round the corner, small- and medium-sized, export-oriented pharmaceutical companies are expecting a 5-10 per cent decline in their bottom line for the April-June period, owing to the rupee appreciation.
Amid the noise around multinational retail chains queuing up to enter India comes a calming revelation. According to management consultancy firm A T Kearney, not all retail biggies continue in the new markets that they enter.
As real estate investment trusts are yet to take shape in India, about a half a dozen realty firms have started the spadework for listing REIT-like vehicles on the Singapore Stock Exchange.
When Mumbai-born architect Mukesh Mehta first waded into Dharavi a decade ago, he went in as - in his own words - a mercenary looking to make money
Another user of the data is the clinical diabetics' consortium, which aims to identify if there are specific genetic reasons for a particular ethnic group to be predisposed to the disease.
The move is in line with the NPPA's recent policy of putting a cap on prices.
The hospital has ordered a new cath-lab and is readying its entire idle capacities to make room for Trehan's surgeons.
In April, Mumbai-based pharmaceutical company Wockhardt announced it had received five marketing approvals for its generic medicines, versions of those that have gone off patents, from the US Food and Drug Administration in five weeks.
Hiranandani, K Raheja Builders, Gamon Infrastructure and Kalpataru are reported to have shown interest in the Rs 9,300-crore project, launched by the Slum Rehabilitation Authority (SRA) of the Maharashtra government.
India's biggest realty firm, DLF is betting on special economic zones (SEZs). The zones will cover an area of 26,100 acres and the company expects to take control of the land in the next two years.
Lack of uniform valuation and disclosure standards could dampen the enthusiasm of investors in real state mutual funds once they are launched in the country.
Raghavendra Kamath and Ashutosh Joshi spoke to Kushal Pal Singh on the growth of Indian realty story and issues surrounding it.
Ranbaxy earned $114 million from its US operations in 2006. It launched 10 new products during the year. The company said that the revenues from the sale of the newly acquired brands would be reflected from the next quarter.
Shivinder's dream project, of course, is the Medicity he wants to put up at Gurgaon on the outskirts of New Delhi. That is where the problem with Trehan began, who has his own plans to come up with a similar project at Gurgaon.
Mumbai-based real estate firm Lodha Developers plans a public issue by the year-end to raise between Rs 2,000 and 2,500 crore (Rs 20 to Rs 25 billion), according to sources.
Following hectic negotiations, Fortis Healthcare managing director Shivinder Singh and Naresh Trehan have finally smoked the peace pipe
After making big-ticket acquisitions abroad, leading Indian pharmaceutical companies like Dr Reddy's Laboratories, Ranbaxy Laboratories, and Aurobindo Pharma are rapidly shifting production to their Indian facilities.
Buckling under pressure from mill land developers, the Maharashtra government is considering reducing the value of textile mill lands in its Stamp Duty Ready Reckoner
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances